Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Research / Clinical Trials / Study Details

Study Evaluating KTE-X19 in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Research Question:
Is the drug KTE-X19 safe and effective in treating acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL)?

Basic Study Information

This study will determine if the drug KTE-X19 is safe and effective in treating in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).

Location: University of Rochester Medical Center
Study Reference #: IBMT19101

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485

Additional Study Details

Return to Search